Press release
X-Linked Retinitis Pigmentosa Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight
X-Linked Retinitis Pigmentosa Clinical Trials
In the X-Linked Retinitis Pigmentosa Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, X-Linked Retinitis Pigmentosa NDA approvals (if any), and product development activities comprising the technology, X-Linked Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the X-Linked Retinitis Pigmentosa Pipeline treatment landscape of the report, click here @ X-Linked Retinitis Pigmentosa Pipeline Outlook- https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the X-Linked Retinitis Pigmentosa Pipeline Report
• DelveInsight's X-Linked Retinitis Pigmentosa Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading companies working in the X-Linked Retinitis Pigmentosa market include Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
• PromisingX-Linked Retinitis Pigmentosa Pipeline Therapies in the various stages of development include Genetic: AAV5-RPGR, AAV2/5-RPGR, FT-002, Docosahexaenoic Acid OR corn/Soy Oil placebo, and others.
• April 2024:- Janssen Pharmaceuticals- Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR). The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).
• April 2024:- Beacon Therapeutics- A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa. This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
X-Linked Retinitis Pigmentosa Overview
X-linked Retinitis Pigmentosa is a rare, hereditary progressive genetic disorder associated with the gene mutation in chromosome X of an individual. This disorder is characterized by the progressive degeneration of photoreceptor cells in the retina and gradually leading to peripheral vision loss.
For further information, refer to the detailed X-Linked Retinitis Pigmentosa Unmet Needs, click here for X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
X-Linked Retinitis Pigmentosa Emerging Drugs Profile
• BIIB 112 (NSR-RPGR): Biogen
• 4D-125: 4 D Molecular Therapeutics
X-Linked Retinitis Pigmentosa Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for X-linked Retinitis Pigmentosa. The companies which have their X-linked Retinitis Pigmentosa drug candidates in the mid to advanced stage, Phase II/III include, Biogen and others.
Request a sample and discover the recent advances in X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis and Medications, Click here for more details @ X-Linked Retinitis Pigmentosa Segmentation- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
X-Linked Retinitis Pigmentosa Drugs and Companies
• Genetic: AAV5-RPGR: MeiraGTx UK II Ltd
• FT-002: Frontera Therapeutics
• Docosahexaenoic Acid OR Corn/Soy Oil Placebo: Retina Foundation of the Southwest/ DSM Nutritional Products Inc.
X-Linked Retinitis Pigmentosa Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the X-Linked Retinitis Pigmentosa Therapeutics Market include-
Biogen, 4D Molecular Therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
Dive deep into rich insights for drugs for the X-Linked Retinitis Pigmentosa Pipeline, Click here @ X-Linked Retinitis Pigmentosa Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the X-Linked Retinitis Pigmentosa Pipeline Report
• Coverage- Global
• Companies- Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
• Therapies- Genetic: AAV5-RPGR, AAV2/5-RPGR, FT-002, Docosahexaenoic Acid OR corn/Soy Oil placebo, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on X-Linked Retinitis Pigmentosa Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. X-linked Retinitis Pigmentosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. X-linked Retinitis Pigmentosa - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. X-linked Retinitis Pigmentosa Collaboration Deals
9. Late Stage Products (Phase II/III)
10. BIIB 112 (NSR-RPGR): Biogen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase I/II)
13. 4D-125: 4 D Molecular Therapeutics
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. X-linked Retinitis Pigmentosa Key Companies
19. X-linked Retinitis Pigmentosa Key Products
20. X-linked Retinitis Pigmentosa- Unmet Needs
21. X-linked Retinitis Pigmentosa- Market Drivers and Barriers
22. X-linked Retinitis Pigmentosa- Future Perspectives and Conclusion
23. X-linked Retinitis Pigmentosa Analyst Views
24. X-linked Retinitis Pigmentosa Key Companies
25. Appendix
Trending Report:
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Ashermans Syndrome Market: https://www.delveinsight.com/sample-request/ashermans-syndrome-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Hepatitis D Market: https://www.delveinsight.com/report-store/hepatitis-d-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Community-acquired Bacterial Pneumonia Market: https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market
• Familial Amyloid Polyneuropathy Market: https://www.delveinsight.com/report-store/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrades-disease-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/business-development-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release X-Linked Retinitis Pigmentosa Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight here
News-ID: 3850039 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Retinitis
Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic…
Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic…
Retinitis Pigmentosa Market Growth and Treatment Advancements
The retinitis pigmentosa (RP) market has garnered considerable attention in recent years due to its profound impact on individuals' lives. As one of the leading causes of hereditary blindness, RP is a genetic eye disorder that progressively leads to vision loss. The market for retinitis pigmentosa treatments was valued at USD 14.02 billion in 2023, and with significant advancements on the horizon, it is expected to reach USD 21.40 billion…
Retinitis Pigmentosa Market Research and Market Share Insights
The Business Research Company recently released a comprehensive report on the Global Retinitis Pigmentosa Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Retinitis Pigmentosa (Retinitis) Market Analysis and Future Prospects for 2030
The world of the retinitis pigmentosa (retinitis) market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing…
